Open AccessPembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
Author(s) -
Charles M. Rudin,
Mark M. Awad,
Alejandro Navarro,
Maya Gottfried,
Solange Peters,
Tibor Csőszi,
Parneet Cheema,
D. Rodríguez Abreu,
Mirjana Wollner,
James ChihHsin Yang,
Julien Mazières,
F Orlandi,
Alexander Luft,
Mahmut Gümüş,
Terufumi Kato,
Gregory P. Kalemkerian,
Yang Luo,
Victoria Ebiana,
M. Catherine Pietanza,
Hye Ryun Kim,
Keynote Investigators
Publication year - 2020
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.20.00793
Subject(s) - pembrolizumab , medicine , placebo , lung cancer , hazard ratio , clinical endpoint , population , etoposide , gastroenterology , surgery , oncology , randomized controlled trial , confidence interval , cancer , chemotherapy , immunotherapy , pathology , alternative medicine , environmental health
Pembrolizumab monotherapy has shown antitumor activity in patients with small-cell lung cancer (SCLC). The randomized, double-blind, phase III KEYNOTE-604 study compared pembrolizumab plus etoposide and platinum (EP) with placebo plus EP for patients with previously untreated extensive-stage (ES) SCLC.